Jade Biosciences Inc (JBIO) FinancialsJBIOJade Biosciences Inc

Evaluating the bottom line, Jade Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.80%, provide a clear picture of how effectively JBIO converts its operational activities into shareholder value.

In the context of the broader market, JBIO competes directly with industry leaders such as MGTX and VOR. With a market capitalization of $1.57B, it holds a leading position in the sector. When comparing efficiency, JBIO's gross margin of N/A stands against MGTX's 97.77% and VOR's N/A. Such benchmarking helps identify whether Jade Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Jade Biosciences has reported increasing net losses, with a Q2 2026 loss of $55.76 million and a negative EPS of -0.76. However, the company's total equity has grown significantly, reaching $439.91 million in Q2 2026, indicating a solid capital base despite losses.